Metropolitan Life Insurance Company (MetLife)’s NovoCure NVCR Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,810	Closed	-$511K	–	2539
2021 Q4	$511K	Sell	6,810 -53	-0.8%	-$5.32K	0.01%	1407
2021 Q3	$797K	Buy	+6,863	New	+$1.04M	0.01%	1130
2021 Q2	–	Sell	-7,322	Closed	-$968K	–	2821
2021 Q1	$968K	Sell	7,322 -330	-4%	-$52.2K	0.01%	944
2020 Q4	$1.32M	Sell	7,652 -45	-0.6%	-$6.16K	0.02%	696
2020 Q3	$857K	Sell	7,697 -199	-3%	-$15.9K	0.01%	835
2020 Q2	$468K	Sell	7,896 -18,288	-70%	-$1.2M	0.01%	1258
2020 Q1	$1.76M	Sell	26,184 -568	-2%	-$44.9K	0.04%	432
2019 Q4	$2.25M	Sell	26,752 -738	-3%	-$59.6K	0.04%	477
2019 Q3	$2.06M	Buy	27,490 +4,041	+17%	+$323K	0.03%	490
2019 Q2	$1.48M	Hold	23,449	–	–	0.03%	668
2019 Q1	$1.13M	Buy	+23,449	New	+$1.13M	0.02%	822

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s NVCR Position: Q1 2022 in Review

Metropolitan Life Insurance Company (MetLife) sold out of NovoCure (NVCR) in Q1 2022, closing a stake of 6,810 shares — an estimated $511K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in NVCR in Q1 2019 and held it in 11 quarters. The position peaked at $2.25M in Q4 2019. 309 funds tracked by Wall St. Rank hold NVCR as of Q1 2022.

Metropolitan Life Insurance Company (MetLife) reported no remaining NovoCure position as of Q1 2022 after selling out during the quarter.
Metropolitan Life Insurance Company (MetLife) sold 6,810 NovoCure shares in Q1 2022, an estimated $511K.
Metropolitan Life Insurance Company (MetLife) first reported a position in NovoCure in Q1 2019 and held it in 11 quarters.
Metropolitan Life Insurance Company (MetLife)'s NovoCure position peaked at $2.25M in Q4 2019.
309 funds tracked by Wall St. Rank held NovoCure as of Q1 2022.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q1 2022, filed 12 May 2022.